Dr. Wu on Possible Combinations With TAS-102 in CRC

Partner | Cancer Centers | <b>Perlmutter Cancer Center at NYU Langone</b>

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer.

Jennifer Wu, MD, assistant professor of Medicine, Department of Medicine, Perlmutter Cancer Center, NYU Langone Medical Center, discusses potential combinations with TAS-102 for the treatment of patients with colorectal cancer (CRC).

TAS-102 is currently being investigated in combination with oxaliplatin in preclinical models, Wu says. Data reported earlier in 2015 have shown that clinical activity was demonstrated in refractory patients with CRC when TAS-102 was combined with bevacizumab.

Looking ahead, Wu says TAS-102 will be a part of novel combinations in CRC, possibly even with stem cell inhibitors.